61 completed, 15 recruiting, 15 unknown, 14 active not recruiting. 119 Phase 2, 16 Phase 1, 4 Phase 3.
Follow Dacarbazine: new trials by email Literature Review of Dacarbazine trials Research Report on Dacarbazine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment Biospecimen Collection, Brentuximab Vedotin, Computed Tomography - Classic Hodgkin Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 23 | 2027-01-01 | 2026-11-12 |
| Cryoablation Combined With Hepatic Arterial Infusion of Iparomlimab and Tuvonralimab (QL1706), Intravenous Dacarbazine, and Oral Lenvatinib in Patients With Liver Metastases From Malignant Melanoma: a Single-arm, Phase II, Prospective Trial Cryoablation, Iparomlimab and Tuvonralimab, Dacarbazine - Melanoma (Skin) Stage IV | Phase 2 | Recruiting | Sun Yat-sen University | 28 | 2026-10-01 | 2026-09-29 |
| Phase II Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL Nivolumab, Doxorubicin Hydrochloride, Vinblastine - Hodgkin Lymphoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 15 | 2026-08-19 | 2026-08-31 |
| Sintilimab Combined With Chemotherapy for Adjuvant Treatment of Mucosal Melanoma After Surgery Sintilimab, Dacarbazine or Temozolomide, Cisplatin - Mucosal Melanoma, PD-L1 Positive | Phase 2 | Recruiting | The First Hospital of Jilin University | 220 | 2026-04-10 | 2026-09-03 |
| A Phase II Trial of LM103 in Advanced Melanoma LM103 TILs Injection, Dacarbazine, temozolomide, paclitaxel, carboplatin/cisplatin - Advanced Melanoma | Phase 2 | Recruiting | Suzhou BlueHorse Therapeutics Co., Ltd. | 92 | 2025-12-16 | 2026-08-31 |
| Feasibility of Total Neoadjuvant Treatment With HYPErthermia in Patients With High-risk Extremity and Trunk Soft Tissue Sarcoma (TNT-HYPE) Doxorubicin, Ifosfamide, Dacarbazine - Sarcoma,Soft Tissue | Phase 2 | Recruiting | Swiss Cancer Institute | 24 | 2025-10-27 | 2025-12-30 |
| A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma LNS8801, Pembrolizumab, Chemotherapy (dacarbazine or temozolomide) - Melanoma (Skin Cancer), Melanoma Stage IIIB-IV | Phase 2 / Phase 3 | Recruiting | Linnaeus Therapeutics, Inc. | 135 | 2025-08-06 | 2026-04-22 |
| BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma Brentuximab Vedotin, Etoposide, Cyclophosphamide - Hodgkin Lymphoma, Advanced Hodgkin Lymphoma | Phase 2 | Recruiting | University of Miami | 48 | 2025-07-15 | 2026-11-18 |
| Nivo40-AVD for Advanced Classic Hodgkin Lymphoma Nivolumab, Doxorubicin, Vinblastine - Hodgkin Lymphoma, Adult | Phase 2 | Recruiting | National Medical Research Radiological Centre of the Ministry of Health of Russia | 54 | 2025-04-15 | 2025-11-26 |
| Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma Biospecimen Collection, Computed Tomography, Dacarbazine - Advanced Hodgkin Lymphoma, Classic Hodgkin Lymphoma | Phase 2 | Recruiting | University of Washington | 125 | 2025-03-06 | 2026-09-09 |
| A Study of GC101 TIL in Advanced Melanoma GC101 TIL, dacarbazine, temozolomide, paclitaxel ,platinum or cisplatin - Melanoma | Phase 2 | Recruiting | Shanghai Juncell Therapeutics | 98 | 2024-12-20 | 2026-08-05 |
| Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment Brentuximab Vedotin for Injection, response-adapted radiation, Doxorubicin - Classical Hodgkin Lymphoma, Child | Phase 2 / Phase 3 | Recruiting | Children's Cancer Group, China | 96 | 2024-09-25 | 2026-03-19 |
| A Study of BV-AVD in People With Bulky Hodgkin Lymphoma Brentuximab vedotin, Doxorubicin, Vinblastine - Hodgkin Lymphoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 71 | 2024-04-17 | 2026-04-23 |
| Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin Lymphoma Biopsy, Biospecimen Collection, Computed Tomography - Classic Hodgkin Lymphoma | Phase 2 | Active not recruiting | Northwestern University | 30 | 2024-02-06 | 2026-07-13 |
| PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma Brentuximab vedotin, Doxorubicin Hydrochloride, Pembrolizumab - Hodgkin Lymphoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 25 | 2023-12-14 | 2026-10-06 |
| IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma IDE196, Crizotinib, Pembrolizumab - Metastatic Uveal Melanoma | Phase 2 / Phase 3 | Active not recruiting | IDEAYA Biosciences | 420 | 2023-10-31 | 2026-02-17 |
| Doxorubicin Plus Dacarbazine Versus Doxorubicin Alone as First-Line Therapy for Metastatic or Recurrent Uterine Leiomyosarcoma Doxorubicin, dacarbazine - Leiomyosarcoma, Uterine Leiomyosarcoma | Phase 2 | Recruiting | Blokhin's Russian Cancer Research Center | 100 | 2023-01-24 | 2026-11-17 |
| PD-1 Antibody Tislelizumab Combined With Dacarbazine in the Treatment of Advanced Melanoma Tislelizumab Injection - Advanced Melanoma | Phase 2 | Unknown | Henan Cancer Hospital | 40 | 2022-12-30 | 2023-10-24 |
| BV-AVD-R Treatment Children Hodgkin's Lymphoma Brentuximab vedotin, Rituximab, Doxorubicin - Hodgkin Lymphoma | Phase 2 | Unknown | Beijing Children's Hospital | 44 | 2022-10-01 | 2024-01-12 |
| Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above Pembrolizumab, Doxorubicin, Vinblastine - Classical Hodgkin Lymphoma | Phase 2 | Active not recruiting | University of Virginia | 24 | 2022-07-26 | 2026-05-14 |
Showing 20 of 119. Sign in to see all of them.
Melanoma (44) · Hodgkin Disease (32) · Lymphoma (10) · Sarcoma (9) · Neoplasm Metastasis (6) · Uveal Melanoma (6) · Leiomyosarcoma (5) · Neoplasms (4) · HIV Infections (3) · Parkinson Disease 4, Autosomal Dominant Lewy Body (2) · Sarcoma, Synovial (2) · Skin Neoplasms (2) · Solitary Fibrous Tumors (2) · AIDS-Related Complex (1) · Acquired Immunodeficiency Syndrome (1)
M.D. Anderson Cancer Center (6) · National Cancer Institute (NCI) (4) · Memorial Sloan Kettering Cancer Center (3) · Merck Sharp & Dohme LLC (3) · Northwestern University (3) · Philogen S.p.A. (3) · Bayer (2) · Bristol-Myers Squibb (2) · City of Hope Medical Center (2) · European Organisation for Research and Treatment of Cancer - EORTC (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · Henan Cancer Hospital (2) · Massachusetts General Hospital (2) · Radiation Therapy Oncology Group (2) · Seagen Inc. (2)
United States (71) · Germany (22) · Italy (19) · Spain (15) · Canada (14) · France (14) · United Kingdom (14) · China (12) · Netherlands (12) · Switzerland (11) · Australia (9) · Belgium (9) · Poland (8) · Brazil (5) · Russia (5)
Adil Daud, M.D. (2) · Anas Younes, MD (2) · Claus Garbe, Prof. M.D. (2) · Agop Y. Bedikian, MD (1) · Alba Rubio (1) · Albrecht Reichle, Professor (1) · Aleksei V. Novik, MD, PhD (1) · Alex F Herrera (1) · Alison Moskowitz, MD (1) · Anatolij D Namgaladze, Master (1)
PMID 40135712, PMID 37505794, PMID 11904735, PMID 16051328, PMID 16170182, PMID 16446334, PMID 16826357, PMID 17023156, PMID 17443000, PMID 18445842, PMID 20564083, PMID 20572040, PMID 21079154, PMID 21750549, PMID 22028492, PMID 22371887, PMID 23077008, PMID 23735514, PMID 24359243, PMID 24930625, PMID 24938562, PMID 25086465, PMID 26377597, PMID 26407818, PMID 27451390, PMID 27465021, PMID 27596353, PMID 27921276, PMID 28327988, PMID 28439879, PMID 28961465, PMID 29038340, PMID 29177094, PMID 29280762, PMID 29394125, PMID 29584546, PMID 29681762, PMID 30049811, PMID 30179569, PMID 30202085, PMID 30723079, PMID 30736858, PMID 31112476, PMID 31186274, PMID 31331918, PMID 31371315, PMID 31395089, PMID 31401903, PMID 32305010, PMID 32352505
2004 (2), 2014 (2), 2023 (2), P30CA060553 (2), U10CA180821 (2), 2005 (1), 2008 (1), 2009 (1), 2015 (1), 2017 (1), M01RR000096 (1), N01CM00070 (1), N01CM00071 (1), N01CM00099 (1), N01CM00100 (1)